Metastatic colon carcinoma detected with radiolabeled F(ab')2 monoclonal antibody fragments.

Publisher Website
Google Scholar
Abstract
Nine patients with colonic carcinoma were studied with 131I-labeled F(ab'')2 fragments of an anti-colorectal carcinoma monoclonal antibody. A total of 69% of colon cancer sites were detected without background subtraction; metastases from a concurrent breast carcinoma in 1 patient were not seen. Lesions ranged from 1.5-8 cm. The mean thyroid uptake of 131I at 24 h was 0.25%. Half-lives of 131I in the blood (protein-bound and total) fit a 2 compartment model, with half-lives of 3.5 and 27.6 h for the protein-bound fraction and 3.6 and 23.8 h for total 131I. Using quantitative methods, a mean value of 0.0047%/cm3 of the administered dose was localized in the tumor at peak concentration, which occurred .apprx. 48 h post-administration. This has implications for therapy planning.